Clinical Trials
16 trialsNCT03745326 2026-05-19
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT05035407 2025-12-02
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01369875 2019-12-10
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02153905 2019-06-17
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01814046 2018-10-11
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00089778 2017-08-01
Vaccine Treatment of Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01271907 2017-08-01
Drosophila-generated CTL
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00612222 2015-10-28
Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00924287 2015-10-28
Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01160445 2015-10-28
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01273181 2015-10-28
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00303836 2013-06-06
Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00054405 2013-04-09
Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00052377 2013-01-16
Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00509496 2013-01-15
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00091611 2012-10-26
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated